טוען...
Omalizumab as a Provoking Factor for Venous Thromboembolism
A 43-year-old man with a history of severe extrinsic allergic asthma treated with once-monthly omalizumab (600 mg) for the last 15 months. He presented to the emergency room with a 2-week history of right lower limb pain and chest pleuritic pain. Computed tomography pulmonary angiography showed bila...
שמור ב:
| הוצא לאור ב: | Drug Target Insights |
|---|---|
| Main Authors: | , , , , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
SAGE Publications
2019
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6611017/ https://ncbi.nlm.nih.gov/pubmed/31320796 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/1177392819861987 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|